Premium
Claudin‐1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate
Author(s) -
Krajewska Maryla,
Olson Allen H.,
Mercola Dan,
Reed John C.,
Krajewski Stan
Publication year - 2007
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20578
Subject(s) - claudin , pathology , prostate , tissue microarray , immunohistochemistry , cytokeratin , tight junction , immunostaining , intraepithelial neoplasia , epithelium , hyperplasia , adenocarcinoma , prostate cancer , medicine , biology , cancer , microbiology and biotechnology
BACKGROUND Claudins are a family of approximately 23 integral membrane tight junction (TJ) proteins that maintain cell polarity and paracellular barrier functions in epithelial and endothelial cells. Although Claudin‐1 was demonstrated to be typically downregulated in various cancers, the precise expression patterns of this protein in normal and neoplastic tissues remain poorly characterized. METHODS Using immunohistochemistry, the expression of Claudin‐1 was investigated in prostate tissue samples arranged in a tissue microarray (TMA) format and comprising elements of normal prostatic epithelium (n = 6), benign prostatic hyperplasia (BPH; n = 38), prostatic intraepithelial neoplasia (PIN; n = 11), and prostate adenocarcinoma (n = 48). The Claudin‐1 expression pattern was compared with that of the basal cell‐specific markers, p63, and HMW cytokeratin (34βE12), by employing double‐labeling techniques in conjunction with image analysis methods utilizing color deconvolution algorithms. RESULTS In benign prostatic epithelium, pronounced Claudin‐1 expression was observed in the basal cell layer with no staining in luminal cells. Prostate adenocarcinoma specimens from 98% (47/48) patients lacked Claudin‐1 immunostaining, and no cases contained >5% immunopositive tumor cells. CONCLUSIONS Claudin‐1 immunohistochemistry should be considered for use as a new diagnostic tool for distinguishing malignant from benign lesions of the prostate. Prostate 67: 907–910, 2007. © 2007 Wiley‐Liss, Inc.